


Hypoplastic Left Heart Syndrome (HLHS) Consortium



Children’s Minnesota is proud to be one of 11 participants in the Todd and Karen Wanek Family Program for HLHS at Mayo Clinic, a nationwide collaboration that seeks to discover new therapies to treat HLHS. The consortium provides patients with a unique opportunity to participate in groundbreaking clinical trials and other research — regardless of their location.

The consortium has identified the highest-performing programs for HLHS nationally. These centers are the clinical sites for umbilical cord blood-derived stem cell therapy trials for patients with HLHS. The network allows HLHS researchers to pool scientific knowledge with other top cardiovascular programs around the country, reducing the time it takes to transform discoveries from the bench into promising new therapies at the bedside.

The program’s mission is to support education and research on why and how heart disease develops and progresses and collaborate in developing cell-based therapies to repair heart tissue. The long-term goal is to delay or prevent heart failure in people with HLHS.